Corrigendum to “Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6” [J Crohns Colitis 8S1 (2014) P497 S274-5]
William J. Sandborn(University of San Diego), Irving H. Fox(Takeda (United States)), Walter Reinisch(Medical University of Vienna), A. Parikh(Takeda (United States)), Brian G. Feagan(Western University), Michael Smyth, Jing Xu(Kunming Medical University)
Cited by 7
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k